.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,780,485

« Back to Dashboard

Claims for Patent: 5,780,485

Title: Use of .alpha..sub.1c specific compounds to treat benign prostatic hyperplasia
Abstract:A method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human .alpha..sub.1C adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human .alpha..sub.1A adrenergic receptor, a human .alpha..sub.1B adrenergic receptor, and a human histamine H.sub.1 receptor, and, binds to a human .alpha..sub.2 adrenergic receptor with a binding affinity which is greater than ten-fold lower than the binding affinity with which the compound binds to such .alpha..sub.1C adrenergic receptor. Compounds meeting these criteria are provided.
Inventor(s): Gluchowski; Charles (Wayne, NJ), Forray; Carlos C. (Waldwick, NJ), Chiu; George (Bridgewater, NJ), Branchek; Theresa A. (Teaneck, NJ), Wetzel; John M. (Elmwood Park, NJ), Hartig; Paul R. (Princeton, NJ)
Assignee: Synaptic Pharmaceutical Corporation (Paramus, NJ)
Application Number:08/415,681
Patent Claims: 1. A method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of an antagonist which binds to a human .alpha..sub.1C adrenergic receptor with a binding affinity at least 48-fold higher than the binding affinity with which the antagonist binds to a human .alpha..sub.1B adrenergic receptor.

2. The method of claim 1, wherein the binding affinity of the antagonist is at least 10-fold higher for the human .alpha..sub.1C adrenergic receptor than it is for a human .alpha..sub.1A adrenergic receptor or a human .alpha..sub.2 adrenergic receptor.

3. The method of claim 1, wherein the binding affinity of the antagonist is at least 10-fold higher for the human .alpha..sub.1C adrenergic receptor than it is for a human histamine H.sub.1 receptor.

4. The method of claim 1, wherein the binding affinity of the antagonist is at least 10-fold higher for the human .alpha..sub.1C adrenergic receptor than it is for a calcium channel.

5. The method of claim 1, wherein the binding affinity of the antagonist is at least 10-fold higher for the human .alpha..sub.1C adrenergic receptor than it is for a human dopamine D.sub.2 receptor.

6. The method of claim 1, wherein the binding affinity of the antagonist is at least 10-fold higher for the human .alpha..sub.1C adrenergic receptor than it is for a human serotonin receptor.

7. The method of claim 1, wherein the binding affinity of the antagonist is at least 10-fold higher for the human .alpha..sub.1C adrenergic receptor than it is for a human dopamine D.sub.3, D.sub.4, or D.sub.5 receptor.

8. The method of claim 1, wherein the binding affinity of the antagonist is at least 200-fold higher for the human .alpha..sub.1C adrenergic receptor than it is for the human .alpha..sub.1B adrenergic receptor.

9. The method of claim 8, wherein the binding affinity of the antagonist is at least 51-fold higher for the human .alpha..sub.1C adrenergic receptor than it is for the human histamine H.sub.1 receptor.

10. A method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of an antagonist which binds to a human .alpha..sub.1C adrenergic receptor with a binding affinity at least 26-fold higher than the binding affinity with which the antagonist binds to a human .alpha..sub.1B adrenergic receptor.

11. The method of claim 3, wherein the binding affinity of the antagonist is at least 65-fold higher for the human .alpha..sub.1C adrenergic receptor than it is for the human histamine H.sub.1 receptor.

12. The method of claim 3, wherein the binding affinity of the antagonist is at least 93-fold higher for the human .alpha..sub.1C adrenergic receptor than it is for the human histamine H.sub.1 receptor.

13. A method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of an antagonist which binds to a human .alpha..sub.1C adrenergic receptor with a binding affinity at least 35-fold higher than the binding affinity with which the antagonist binds to a human .alpha..sub.1A adrenergic receptor and at least 417-fold higher than it is for a human histamine H.sub.1 receptor.

14. The method of claim 10, wherein the binding affinity of the antagonist is at least 91-fold higher for the human .alpha..sub.1C adrenergic receptor than it is for the human .alpha..sub.1A adrenergic.

15. The method of claim 2, wherein the binding affinity of the antagonist is at least 107-fold higher for the human .alpha..sub.1C adrenergic receptor than it is for the human .alpha..sub.1A adrenergic receptor.

16. The method of claim 8, wherein the binding affinity of the antagonist is at least 776-fold higher for the human .alpha..sub.1C adrenergic receptor than it is for the human .alpha..sub.1A adrenergic receptor.

17. The method of claim 3, wherein the binding affinity of the antagonist is at least 28-fold higher than it is for a human .alpha..sub.2 adrenergic receptor.

18. The method of claim 10, wherein the binding affinity of the antagonist for the human .alpha..sub.1C adrenergic receptor is (i) at least 91-fold higher than it is for the human .alpha..sub.1A adrenergic receptor, (ii) at least 65-fold higher than it is for the human histamine H.sub.1 receptor, and (iii) at least 229-fold higher than it is for the human .alpha..sub.2 adrenergic receptor.

19. The method of claim 1, wherein the binding affinity of the antagonist for the human .alpha..sub.1C adrenergic receptor is (i) at least 107-fold higher than it is for the human .alpha..sub.1A adrenergic receptor, (ii) at least 93-fold higher than it is for the human histamine H.sub.1 receptor, and (iii) at least 209-fold higher than it is for the human .alpha..sub.2 adrenergic receptor.

20. The method of claim 1, wherein the binding affinity of the antagonist for the human .alpha..sub.1C adrenergic receptor is (i) at least 776-fold higher than it is for the human .alpha..sub.1A adrenergic receptor, (ii) at least 200-fold higher than it is for the human .alpha..sub.1B adrenergic receptor, (iii) at least 51-fold higher than it is for the human histamine H.sub.1 receptor, and (iv) at least 871-fold higher than it is for the human .alpha..sub.2 adrenergic receptor.

21. The method of claim 10, wherein the binding affinity of the antagonist for the human .alpha..sub.1C adrenergic receptor is at least 41-fold higher than it is for the calcium channel.

22. The method of claim 8, wherein the binding affinity of the antagonist for the human .alpha..sub.1C adrenergic receptor is at least 550-fold higher than it is for the calcium channel.

23. The method of claim 8, wherein the binding affinity of the antagonist for the human .alpha..sub.1C adrenergic receptor is at least 25-fold higher than it is for a human histamine H.sub.2 receptor.

24. The method of claim 10, wherein the binding affinity of the antagonist for the human .alpha..sub.1C adrenergic receptor is at least 234-fold higher than it is for a human histamine H.sub.2 receptor.

25. The method of claim 3, wherein the binding affinity of the antagonist for the human .alpha..sub.1C adrenergic receptor is at least 324-fold higher than it is for a human histamine H.sub.2 receptor.

26. The method of claim 10, wherein the binding affinity of the antagonist for the human .alpha..sub.1C adrenergic receptor is at least 30-fold higher than it is for the human serotonin receptor.

27. The method of claim 6, wherein the binding affinity of the antagonist for the human .alpha..sub.1C adrenergic receptor is at least 56-fold higher than it is for the human serotonin receptor.

28. The method of claim 8, wherein the binding affinity of the antagonist for the human .alpha..sub.1C adrenergic receptor is at least 74-fold higher than it is for the human serotonin receptor.

29. A method of inhibiting contraction of prostatic tissue which comprises contacting the prostate tissue with an effective contraction-inhibiting amount of an antagonist which binds to a human .alpha..sub.1C adrenergic receptor with a binding affinity at least 48-fold higher than the binding affinity with which the antagonist binds to a human .alpha..sub.1B adrenergic receptor.

30. The method of claim 29, wherein the binding affinity of the antagonist is at least 10-fold higher for the human .alpha..sub.1C adrenergic receptor than it is for a human .alpha..sub.1A adrenergic receptor or a human .alpha..sub.2 adrenergic receptor.

31. The method of claim 29, wherein the binding affinity of the antagonist is at least 10-fold higher for the human .alpha..sub.1C adrenergic receptor than it is for a human histamine H.sub.1 receptor.

32. The method of claim 29, wherein the binding affinity of the antagonist is at least 10-fold higher for the human .alpha..sub.1C adrenergic receptor than it is for a calcium channel.

33. The method of claim 29, wherein the binding affinity of the antagonist is at least 10-fold higher for the human .alpha..sub.1C adrenergic receptor than it is for a human dopamine D.sub.2 receptor.

34. The method of claim 29, wherein the binding affinity of the antagonist is at least 10-fold higher for the human .alpha..sub.1C adrenergic receptor than it is for a human serotonin receptor.

35. The method of claim 29, wherein the binding affinity of the antagonist is at least 10-fold higher for the human .alpha..sub.1C adrenergic receptor than it is for a human dopamine D.sub.3, D.sub.4, or D.sub.5 receptor.

36. The method of claim 29, wherein the binding affinity of the antagonist is at least 200-fold higher for the human .alpha..sub.1C adrenergic receptor than it is for the human .alpha..sub.1B adrenergic receptor.

37. The method of claim 36, wherein the binding affinity of the antagonist is at least 51-fold higher for the human .alpha..sub.1C adrenergic receptor than it is for the human histamine H.sub.1 receptor.

38. A method of inhibiting contraction of prostatic tissue which comprises contacting the prostate tissue with an effective contraction-inhibiting amount of an antagonist which binds to a human .alpha..sub.1C adrenergic receptor with a binding affinity at least 26-fold higher than the binding affinity with which the antagonist binds to a human .alpha..sub.1B adrenergic receptor.

39. The method of claim 38, wherein the binding affinity of the antagonist is at least 65-fold higher for the human .alpha..sub.1C adrenergic receptor than it is for the human histamine H.sub.1 receptor.

40. The method of claim 31, wherein the binding affinity of the antagonist is at least 93-fold higher for the human .alpha..sub.1C adrenergic receptor than it is for the human histamine H.sub.1 receptor.

41. A method of inhibiting contraction of prostatic tissue which comprises contacting the prostate tissue with an effective contraction-inhibiting amount of an antagonist which binds to a human .alpha..sub.1C adrenergic receptor with a binding affinity at least 35-fold higher than it is for a human .alpha..sub.1A adrenergic receptor and at least 417-fold higher than it is for a human histamine H.sub.1 receptor.

42. The method of claim 38, wherein the binding affinity of the antagonist is at least 91-fold higher for the human .alpha..sub.1C adrenergic receptor than it is for the human .alpha..sub.1A adrenergic receptor.

43. The method of claim 30, wherein the binding affinity of the antagonist is at least 107-fold higher for the human .alpha..sub.1C adrenergic receptor than it is for the human .alpha..sub.1A adrenergic receptor.

44. The method of claim 36, wherein the binding affinity of the antagonist is at least 776-fold higher for the human .alpha..sub.1C adrenergic receptor than it is for the human .alpha..sub.1A adrenergic receptor.

45. The method of claim 41, wherein the binding affinity of the antagonist is at least 28-fold higher than it is for a human .alpha..sub.2 adrenergic receptor.

46. The method of claim 38, wherein the binding affinity of the antagonist for the human .alpha..sub.1C adrenergic receptor is (i) at least 91-fold higher than it is for the human .alpha..sub.1A adrenergic receptor, (ii) at least 65-fold higher than it is for the human histamine H.sub.1 receptor, and (iii) at least 229-fold higher than it is for the human .alpha..sub.2 adrenergic receptor.

47. The method of claim 29, wherein the binding affinity of the antagonist for the human .alpha..sub.1C adrenergic receptor is (i) at least 107-fold higher than it is for the human .alpha..sub.1A adrenergic receptor, (ii) at least 93-fold higher than it is for the human histamine H.sub.1 receptor, and (iii) at least 209-fold higher than it is for the human .alpha..sub.2 adrenergic receptor.

48. The method of claim 29, wherein the binding affinity of the antagonist for the human .alpha..sub.1C adrenergic receptor is (i) at least 776-fold higher than it is for the human .alpha..sub.1A adrenergic receptor, (ii) at least 200-fold higher than it is for the human .alpha..sub.1B adrenergic receptor, (iii) at least 51-fold higher than it is for the human histamine H.sub.1 receptor, and (iv) at least 871-fold higher than it is for the human .alpha..sub.2 adrenergic receptor.

49. The method of claim 38, wherein the binding affinity of the antagonist for the human .alpha..sub.1C adrenergic receptor is at least 41-fold higher than it is for the calcium channel.

50. The method of claim 36, wherein the binding affinity of the antagonist for the human .alpha..sub.1C adrenergic receptor is at least 550-fold higher than it is for the calcium channel.

51. The method of claim 36, wherein the binding affinity of the antagonist for the human .alpha..sub.1C adrenergic receptor is at least 25-fold higher than it is for a human histamine H.sub.2 receptor.

52. The method of claim 38, wherein the binding affinity of the antagonist for the human .alpha..sub.1C adrenergic receptor is at least 234-fold higher than it is for a human histamine H.sub.2 receptor.

53. The method of claim 31, wherein the binding affinity of the antagonist for the human .alpha..sub.1C adrenergic receptor is at least 324-fold higher than it is for a human histamine H.sub.2 receptor.

54. The method of claim 38, wherein the binding affinity of the antagonist for the human .alpha..sub.1C adrenergic receptor is at least 30-fold higher than it is for the human serotonin receptor.

55. The method of claim 34, wherein the binding affinity of the antagonist for the human .alpha..sub.1C adrenergic receptor is at least 56-fold higher than it is for the human serotonin receptor.

56. The method of claim 36, wherein the binding affinity of the antagonist for the human .alpha..sub.1C adrenergic receptor is at least 74-fold higher than it is for the human serotonin receptor.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc